Preclinical food allergy immunotherapy studies have identified modifications in allergen-specific immune responses in mice with reduced allergic disease severity, including enhanced mucosal IgA, a shift in T cell responses, and decreased mast cell activation. This evidence concerns the gene CD79A and food allergy.